Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
PTN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.75%85.851.3%$1342.18m
AMGNAmgen Inc.
0.00%201.561.2%$603.80m
GILDGilead Sciences, Inc.
0.00%68.250.9%$535.10m
LOXOLoxo Oncology Inc
-0.03%233.7012.7%$517.58m
BIIBBiogen Inc.
-0.51%337.221.3%$412.55m
VRTXVertex Pharmaceuticals Incorporated
-0.79%188.401.9%$324.00m
ILMNIllumina, Inc.
0.53%303.893.5%$304.82m
REGNRegeneron Pharmaceuticals, Inc.
0.06%401.442.6%$301.11m
ALXNAlexion Pharmaceuticals, Inc.
0.92%118.082.0%$225.36m
EXASExact Sciences Corporation
4.79%79.7125.3%$149.33m
AAgilent Technologies, Inc.
0.45%71.641.5%$147.28m
INCYIncyte Corporation
2.23%76.882.5%$147.19m
SRPTSarepta Therapeutics, Inc.
-1.30%118.7215.4%$129.31m
LGNDLigand Pharmaceuticals Incorporated
-1.00%111.7823.1%$119.93m
NBIXNeurocrine Biosciences, Inc.
-2.15%89.325.1%$95.56m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.